Advanced search
Publication Cover
Journal of Pain Research Volume 12, 2019 - Issue
Submit an article Journal homepage
88
Views
10
CrossRef citations to date
0
Altmetric
Review

Where should analgesia lead to? Quality of life and functional recovery with tapentadol

Lorenzo Panella1 Rehabilitation Department, ASST Pini-CTO, 20100 Milan, ItalyCorrespondence[email protected]
,
Giuseppe Rinonapoli2 Dipartimento di Scienze Chirurgiche, s.c. Ortopedia e Traumatologia Università di Perugia. Ospedale S.Maria della Misericordia, 06100Perugia, Italy
&
Stefano Coaccioli3 Department of Medicine, Sezione di Clinica Medica e Anatomia Patologia, 05100 Terni, Italy
Pages 1561-1567 | Published online: 16 May 2019

References

  • Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain Lond Engl. 2006;10(4):287–333. doi:10.1016/j.ejpain.2005.06.009
  • Hofmann JF, Lal A, Steffens M, Boettger R. Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-using criteria of health technology assessment. J Opioid Manag. 2016;12(5):323–331. doi:10.5055/jom.2016.034927844472
  • Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005;21(10):1555–1568. doi:10.1185/030079905X6532116238895
  • Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605.20091598
  • Whittle SL, Richards BL, Husni E, et al. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev. 2011;(11):CD003113.22071805
  • Becker. 1997. 
  • Stanos S, Brodsky M, Argoff C, et al. Rethinking chronic pain in a primary care setting. Postgrad Med. 2016;128(5):502–515. doi:10.1080/00325481.2016.118831927166559
  • Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14(8):781–783. doi:10.1016/j.ejpain.2010.06.01720659810
  • Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load’. Adv Ther. 2018;35:1471–1484. doi:10.1007/s12325-018-0778-x30206823
  • Tzschentke TM, Folgering JH, Flik G, De Vry J. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci Lett. 2012;507(2):151–155. doi:10.1016/j.neulet.2011.12.00822197547
  • Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10(4):217–221. doi:10.1177/204946371665736327867511
  • Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opin Drug Discov. 2018;13:965–972. doi:10.1080/17460441.2018.151153930175624
  • Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27(6):381–399. doi:10.1007/s12325-010-0036-320556560
  • Lange B, von Zabern D1, Elling C1, Dubois C1. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr Med Res Opin. 2017;33(8):1413–1422. doi:10.1080/03007995.2017.133518828537506
  • Baron R, Jansen JP, Binder A, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone pr in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract. 2016;16(5):600–619. doi:10.1111/papr.1236126554630
  • Ware JE Jr, Donald Sherbourne C, The MOS. 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.1593914
  • The EuroQol Group. EuroQol a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.10109801
  • Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69–77. doi:10.1016/S0022-3999(01)00296-311832252
  • Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840.3068365
  • Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28(11):1775–1779. doi:10.1185/03007995.2012.73915123057488
  • Cepeda MS, Sutton A, Weinstein R, Kim M. Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. Clin J Pain. 2012;28(1):8–13. doi:10.1097/AJP.0b013e318220198321646907
  • Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin. 2014;30(6):1139–1151. doi:10.1185/03007995.2014.89450124528146

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.